The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.
Cernostics offers an assay that analyzes whole-slide digital images with multiplexed fluorescence to help interpret Barrett's esophagus patient biopsies.
The firm will use the proceeds to support commercialization, regulatory, and product development activities, as well as for general working capital purposes.
The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.
Investigators reported on how ctDNA, measured using Natera's patient-specific Signatera assays, corresponded to a patient's disease progression and other biomarkers.
The cell collection device already has FDA clearance, while the firm intends to conduct trials in support of a filing for marketing clearance of the assay.
The test detects methylation status at 31 sites and is used to determine elevated risk for esophageal dysplasia due to chronic gastroesophageal reflux disease.
